Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5837591 | 0.88 | MAPK14 (0.47) | MAPK14JMJD6GRIN1GRIN2B | |
| SCHEMBL5836827 | 0.87 | MAPK14 (0.55) | MAPK14MEN1KMT2AJMJD6GRIN1 | |
| SCHEMBL5837511 | 0.87 | MAPK14 (0.45) | MAPK14MEN1KMT2AGRIN2B | |
| SCHEMBL5836447 | 0.86 | MAPK14 (0.54) | MAPK14MEN1KMT2AJMJD6 | |
| SCHEMBL5836524 | 0.84 | MAPK14 (0.52) | MAPK14GRIN1GRIN2BTGFBR1 | |
| SCHEMBL5836901 | 0.82 | MAPK14 (0.56) | MAPK14MEN1KMT2AJMJD6TGFBR1 | |
| SCHEMBL5836517 | 0.82 | MAPK14 (0.49) | MAPK14MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL5837967 | 0.81 | MAPK14 (0.53) | MAPK14MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL5838717 | 0.81 | MAPK14 (0.47) | MAPK14GRIN1GRIN2B | |
| SCHEMBL5838005 | 0.81 | MAPK14 (0.49) | MAPK14GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056918-B2 | Benzimidazole anti-inflammatory compounds | PFIZER, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1370557-B1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | PFIZER PROD INC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1370557-A1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | Pfizer Products Inc. (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030092749-A1 | Novel benzimidazole anti-inflammatory compounds | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002072576-A1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092749-A1 | Novel benzimidazole anti-inflammatory compounds | MAPK1, JAK1, CNKSR1 | MAPK14 22/4885MEN1 4415/4885KMT2A 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.